Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Retatrutide (LY3437943) is Eli Lillys experimental triple-agonist drug that activates: GLP-1 (Glucagon-like peptide-1) reduces appetite and slows digestion GIP (Glucose-dependent insulinotropic peptide) enhances insulin sensitivity Glucagon receptor increases fat metabolism and energy expenditure In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction rivaling or even surpassing bariatric surgery outcomes
Study 5: Hay 2015, review article on amylin biology Citation: Hay D.L., Chen S., Lutz T.A., et al
Hepatocyte growth factor ameliorates tissue damage and functional recovery after the acute phase in a mouse model of SCI by exerting anti-inflammatory effects through the diminution of LPS-activated macrophages and neutrophil infiltration (Yamane et al., 2018)
Unlike many compounds marketed as anti-aging therapies, GHK-Cu is not merely a cosmetic molecule
By promoting satiety and steady blood sugar control, this treatment supports sustainable weight management when combined with lifestyle guidance and medical oversight
US$ 26.04
US$ 28.77
US$ 24.24
US$ 22.61
US$ 26.36
US$ 24.83
